Widely used:Recently Viewed
Clear All
$565 Mln
--
1.1
--
0
-54.21 %
--
--
--
-1608826
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Allogene Therapeutics (ALLO)
| -14.64 | 13.69 | 29.25 | -9.57 | -51.74 | -36.71 | -- |
|
BSE Sensex
| 13.00 | 0.56 | 2.05 | 23.70 | 11.01 | 16.81 | 12.01 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Allogene Therapeutics (ALLO)
| -48.97 | -57.84 | -40.89 | -2.85 | -3.53 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$564.60 Mln
$0.09 Mln
$0.00 Mln
$444.63 Mln
$94.21 Mln
High
$2.01 - 5.78
209,112,000
NASDAQ: ALLO
South San Francisco, CA
https://www.allogene.com
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic... chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080 Read more
The total asset value of Allogene Therapeutics Inc (ALLO) stood at $ 684 Mln as on 30-Jun-24
The share price of Allogene Therapeutics Inc (ALLO) is $2.74 (NASDAQ) as of 08-Oct-2024 16:00 EDT. Allogene Therapeutics Inc (ALLO) has given a return of -51.74% in the last 3 years.
Allogene Therapeutics Inc (ALLO) has a market capitalisation of $ 565 Mln as on 08-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Allogene Therapeutics Inc (ALLO) is 1.10 times as on 08-Oct-2024, a 65% discount to its peers’ median range of 3.14 times.
Since, TTM earnings of Allogene Therapeutics Inc (ALLO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Allogene Therapeutics Inc (ALLO) and enter the required number of quantities and click on buy to purchase the shares of Allogene Therapeutics Inc (ALLO).
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Arie S. Belldegrun F.A.C.S., M.D.. is Allogene Therapeutics Inc (ALLO), and CFO & Sr. VP is Dr. Arie S. Belldegrun F.A.C.S., M.D..
There is no promoter pledging in Allogene Therapeutics Inc (ALLO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Allogene Therapeutics Inc. (ALLO) | Ratios |
|---|---|
|
Return on equity(%)
|
-54.21
|
|
Operating margin(%)
|
-314941.86
|
|
Net Margin(%)
|
-323780.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Allogene Therapeutics Inc (ALLO) was $0 Mln.
$0.16
